US equities |
SPCX $167.11 ▲+5.13% NVDA $236.43 ▲+1.06% MU $1,064.68 ▼-0.95% TSLA $378.29 ▲+2.08% MSFT $525.13 ▲+1.47% SNDK $1,708.70 ▼-0.66% INTC $117.39 ▼-1.63% META $743.29 ▲+2.09%
FinancialContent

Immuneering Corporation - Class A Common Stock (NQ:IMRX)

4.085 +0.015 (+0.37%)
Delayed Quote Updated: 12:23 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immuneering Corporation - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
News headline image
Expert Ratings for Immuneering ↗
 
Via Benzinga
News headline image
Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Present at the Jefferies Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
News headline image
Analyst Doubles Immuneering Price Target Citing Initial Data Validation ↗
 
Via Benzinga
News headline image
What 7 Analyst Ratings Have To Say About Immuneering ↗
 
Via Benzinga
News headline image
Why Shares of Immuneering Jumped This Week ↗
Immuneering is ready to share information regarding its lead therapy. 
Via The Motley Fool
News headline image
Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 19, 2023 ↗
 
Via Benzinga
News headline image
Looking Into Immuneering's Return On Capital Employed ↗
 
Via Benzinga
News headline image
Immuneering Earnings Preview ↗
 
Via Benzinga
Immuneering's Return On Capital Employed Insights ↗
 
Via Benzinga
News headline image
Immuneering Announces $30 Million Underwritten Offering
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
- Investor call to be held at 9:00 a.m. ET on April 18, 2023 - 
From Immuneering Corporation
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023 ↗
 
Via Benzinga
News headline image
Immuneering Appoints Harold E. Brakewood as Chief Business Officer
Seasoned biopharma executive with global business development, commercialization, and new product planning expertise to support the development of a universal-RAS franchise 
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Present Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
From Immuneering Corporation
Via GlobeNewswire
News headline image
Top 5 Health Care Stocks That Are Ticking Portfolio Bombs ↗
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Announces Participation in March Investor Conferences
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates
Management to host conference call on Monday, March 6 at 4:30 p.m. ET 
From Immuneering Corporation
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023 ↗
 
Via Benzinga
News headline image
Immuneering To Present at Guggenheim 2023 Oncology Conference
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Announces First Patient Dosed in its Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations
From Immuneering Corporation
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >